Second Price Monitoring Extension
A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.
The applicable percentage is set by reference to a security s Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices
The auction call period has been extended in this security by 5 minutes.
Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security s auction call before the execution occurs. A price monitoring extension is activated when the matching process would have otherwise resulted in an execution price that is a pre-determined percentage above or below the price of the most recent automated execution today.
The applicable percentage is set by reference to a security s Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Integrated Diagnostics Holdings ( IDH or the Company ), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan, and Nigeria, announces that, further to its circular posted on 4 December 2020 (the Circular ), at the Extraordinary General Meeting (the EGM ) of the Company held earlier today at the headquarters of IDH Integrated Diagnostics Holdings, Building B216-F7, Smart Village, Giza, Egypt, all resolutions contained in the notice of the meeting appended to the Circular were duly passed. Further information on the resolutions and the voting report will be available on the Company s website at https://investors.idhcorp.com/
UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost
Wed, 23rd Dec 2020 19:50
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Polarean Imaging PLC - medical imaging products developer - Says US Food & Drug Administration approves company s new drug application. FDA acceptance for the filing of Polarean s NDA represents another important step forward for the Company s platform. If approved, Polarean s drug-device technology could provide a new diagnostic option for patients with pulmonary disease, Chief Executive Officer Richard Hullihen says. Polarean adds that Chief Operating Officer Ken West plans to retire as employee of company but to stay involved as a consultant before transitioning to non-executive role.